Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.
Ornithine decarboxylase from Trypanosoma brucei brucei was inhibited by several substrate (ornithine) and product (putrescine) analogs both in vitro and in vivo. Since alpha-difluoromethylornithine is effective for the treatment of experimental and clinical African trypanosomiasis, it was possible that the more potent ornithine and putrescine analogs might be more active in treating the disease. However, only alpha-monofluoromethyldehydroornithine methyl ester was more potent than alpha-difluromethylornithine against mouse trypanosomiasis and warrants further study in model infections.
D000818:Animals; D000518:Eflornithine; D007700:Kinetics; D008297:Male; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology*; D065108:Ornithine Decarboxylase Inhibitors; D011700:Putrescine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014344:Trypanocidal Agents / Q000494:pharmacology*; D014346:Trypanosoma brucei brucei / Q000201:enzymology*; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D065108:Ornithine Decarboxylase Inhibitors; D014344:Trypanocidal Agents; D009952:Ornithine; D011700:Putrescine; D000518:Eflornithine